Targeting EZH2 in combination with translational and kinase signaling inhibitors may thus offer a powerful strategy to overcome lineage plasticity, restore treatment sensitivity, and suppress progression in aggressive PCa. The gene discussed is EZH2; the disease is posterior cortical atrophy.